Anyone interested in Surmodics, Inc. (NASDAQ:SRDX) should probably be aware that the Independent Director, David Dantzker, recently divested US$163k worth of shares in the company, at an average ...
Surmodics, Inc. SRDX is well poised for growth in the coming quarters, courtesy of its solid prospects in the thrombectomy business over the past few months. The optimism, led by a solid first ...
Surmodics, Inc. SRDX demonstrated strong performance in the last reported quarter. Its loss per share was 51.9% narrower than the market estimate and sales beat the same by 8.3%. The strong ...
Given the pending acquisition by GTCR, Surmodics will not be hosting a live webcast and conference call to discuss the third quarter of fiscal 2025 financial results and accomplishments.
* Surmodics Inc- company used $25.9 million of net cash to acquire Creagh Medical and Normedix in fiscal 2016 * Surmodics Inc says company estimates GAAP revenue for fiscal 2017 to be in range of ...
Our AI model demonstrates 18% historical accuracy for SRDX predictions, based on advanced machine learning algorithms trained on over 10 years of market data.
VAR_0__株価予測に影響を与える要因は何か?
当社の分析では、SURMODICS INCの財務指標、Industrial Applications and Servicesセクターの動向、市場センチメント、テクニカル指標、業績データ、株価に影響を与えるマクロ経済要因を考慮しています。